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Endogenous nitric oxide synthesis determines sensitivity to the
pressor effect of salt
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Minneapolis VAMC and University of Minnesota School of Medicine, Minneapolis, Minnesota, USA
Endogenous nitric oxide synthesis determines sensitivity to the pressor
effect of salt. Endogenous nitric oxide plays an important role in
modulation of renal hemodynamics and sodium handling, with in-
creased nitric oxide production inducing renal vasodilation and natri-
uresis. In the normal rat, nitric oxide activity increases as an adaptive
response to increased dietary salt intake, perhaps facilitating natriuresis
and thus blood pressure homeostasis. We hypothesized that impaired
nitric oxide synthetic ability would result in sensitivity to the pressor
effects of high dietary salt intake. Four groups of normal Sprague-
Dawley rats were observed for eight weeks: Control, 0.4% NaC1 chow
and tap water; Salt, 4% NaCl chow and tap water; NAME, 0.4% NaCI
chow and water containing the nitric oxide synthase inhibitor, L-nitro-
arginine-methylester; Salt+NAME, 4% NaCI chow and water contain-
ing L-nitro-arginine-methylester. Compared to Controls, Salt rats dem-
onstrated a significant increase in urinary excretion rate of the stable
nitric oxide metabolites, NO2 and NO3, and had no increase in blood
pressure. Furthermore, Salt rats had no functional or structural evi-
dence of renal injury. In contrast, Salt+ NAME rats demonstrated a
significantly higher blood pressure than NAME rats, and urinary NO2
and NO3 excretion rate did not increase despite high salt intake. After
eight weeks, SaIt+NAME rats had signfficantly impaired renal function
and proteinuria. We conclude that adaptive changes in endogenous NO
production play a critical role in sodium and blood pressure homeosta-
sis. Furthermore, impaired nitric oxide synthase activity may be a
pathogenetic factor in the development of salt-sensitive hypertension.
In 1980, Furchgott and Zawadski [1] demonstrated that
relaxation of vascular tissues induced by acetyicholine was
dependent on the presence of a functionally intact endothelium,
and postulated the release by endothelial cells of a labile factor
termed endothelium-derived relaxing factor or EDRF. Since
this remarkable observation, it has become apparent that EDRF
is nitric oxide (NO) [2—4]. The basic biology of the endogenous
NO system has now been described. To summarize a large body
of work, NO is derived from the terminal guanidino nitrogen
atom of the amino acid, L-arginine [5, 6]. An enzyme, termed
NO synthase (NOS), is involved in the formation of NO and
L-citrulline from L-arginine [7, 81. Synthesis of NO, in vitro and
in vivo, can be inhibited by L-arginine analogues such as
LNG.monomethylarginine (L-NMMA) and L-N°-nitro-argi-
nine-methylester (L-NAME) [9—11]. NO activates a soluble
guanylate cyclase in target tissues inducing a rise in levels of 3',
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5'-cyclic guanosine monophosphate (cGMP) which, acting as a
second messenger, mediates subsequent physiologic effects [12,
131.
Since NO is a very labile substance, direct measurement of
NO in vivo has proven difficult and, therefore, attention has
focused on secondary markers of NO activity. We previously
demonstrated that NO activity in vivo could be correlated with
urinary levels of the second messenger, cGMP [14]. In addition,
NO decomposes rapidly in biologic solutions to form mixtures
of the stable metabolites, nitrite (NO2) and nitrate (NO3) [151.
We have further demonstrated that serum and urine levels of
NO2 and NO3 can also be utilized as markers of endogenous
NO activity in vivo [16, 17]. The level of NO2 and NO3 in
biologic fluids remains the most reliable and specific in vivo
marker of NO activity reported to date. Thus, utilizing current
methodology, activity of the nitric oxide system can be both
quantitated and specifically inhibited in vivo, providing the
necessary tools for the design of experiments.
By observing the effects of endothelium-dependent agonists,
such as acetylcholine [14, 18—21], or conversely by observing
the effects of NOS inhibitors [17, 22—27], in vivo studies have
demonstrated that NO can profoundly influence renal hemody-
namics and excretory function. It has become clear that stim-
ulation of endogenous NO synthesis results in renal vasodila-
tion, natriuresis and diuresis, while both acute and chronic
inhibition of NOS result in systemic hypertension, decreased
glomerular filtration rate (GFR) and renal vasoconstriction. In a
study of normal rats, we recently reported [17] that when the
influence of systemic pressor effects was eliminated, the direct
renal effect of NOS inhibition was decreased sodium and water
excretion. Furthermore, in this same study [17], we demon-
strated that increased dietary salt intake was associated with
increased serum levels and urinary excretion of NO2 and NO3,
as well as increased urinary cGMP excretion. Additionally,
there was a significant correlation between urinary sodium and
NO2 and NO3 excretion rates. We concluded that NO produc-
tion increases in response to increased dietary salt intake in
normal rats and that the NO system participates in the physio-
logic renal adaptation to increased dietary salt intake. It is
possible that this increased NO activity may prevent a pressor
response to high dietary salt intake by inducing vasodilation and
natriuresis.
This concept is supported by the work of Chen and Sanders
[28], who suggested that a defect in NO synthesis may underlie
the phenomenon of salt-sensitive hypertension in Dahi rats.
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These investigators noted that an increased dietary salt load
resulted in increased activity of the NO system in salt-resistant,
but not salt-sensitive Dahi rats. They hypothesized that the
development of salt-sensitive hypertension may be secondary
to a genetically-determined inability to enhance NO synthesis in
response to increased dietary salt load. However, the conclu-
sions of this study were based predominantly on the hemody-
namic response to NO synthase inhibitors and the response to
exogenous L-arginine, rather than direct measurements of NO
production in vivo. Luscher et al [29] also reported decreased
endothelium-dependent relaxations in the aortas of hyperten-
sive Dahl S rats; however, this phenomenon may have been a
result rather than a cause of hypertension, as the defect was
reversed by anti-hypertensive treatment [29].
Therefore, we asked the question: Does a failure of the
normal adaptive increase in NO activity in response to in-
creased dietary salt intake result in salt-sensitive hypertension?
To explore this question we determined whether chronic im-
pairment of NOS activity, induced by oral administration of the
NOS inhibitor, L-NAME [30, 31], renders normal rats sensitive
to the pressor effects of a high dietary salt intake.
Methods
Experimental protocols
Studies were performed in male Sprague-Dawley rats (225 to
250 g; Harlan Sprague-Dawley, Inc., Indianapolis, Indiana,
USA). All experimental protocols utilized were approved by
the Animal Studies Review Committee of the Minneapolis
Veterans Affairs Medical Center. Before initiating experimental
protocols, baseline determinations of body weight and awake
systolic blood pressure by the tail-cuff method (Programmed
Electro-Sphygmomanometer, Narco Bio-Systems, Houston,
Texas, USA) were performed. All rats were placed in metabolic
cages for 24-hour urine collections which were analyzed for
sodium and NO2 and NO3 content. Rats were then divided into
five experimental groups (N = 8 in each group) in which food
and water were provided ad libitum. Control rats received
standard rat chow (0.4% NaC1, Teklad, Madison, Wisconsin,
USA) and tap water. Salt rats received 4% NaCI chow that was
otherwise matched for mineral, protein and calorie content
(Teklad) and tap water. NAME rats received standard chow
and drinking water which contained the NOS inhibitor,
L-NAME. Salt+NAME rats received 4% NaCl chow and
drinking Water with L-NAME (25 mg/liter). To control for the
observed increased water intake by the Salt+NAME rats, the
concentration of L-NAME in the water of the NAME rats was
adjusted every two weeks to match the dose of L-NAME taken
by the Salt+NAME rats. The average concentration of
L-NAME in the drinking water of NAME rats was 45 mg/liter.
An additional group of rats was given the 4% salt chow and
L-NAME (25 mg/liter in the drinking water); L-arginine was
added to drinking water at a concentration of 250 mg/liter. After
three weeks, the concentration of L-arginine in the drinking
water was increased to 20 g/liter (2%).
At 2, 4, 6 and 8 weeks, rats were weighed and awake systolic
blood pressures were determined. At 2 and 8 weeks, 24-hour
urine collections were performed and analyzed for sodium
content and NO2 and NO3 excretion rate. At eight weeks the
urinary protein excretion rate was also determined. At the end
of the experimental period renal clearance studies for determi-
nation of mean arterial pressure (MAP) and renal hemodynam-
ics were performed as described below. The left kidney was
weighed and processed for morphological analysis.
Clearance studies
Rats were anesthetized (mactin, 100 mg/kg i.p.) and surgi-
cally prepared for determination of mean intra-arterial pressure
(MAP) and renal hemodynamics as previously described [14,
17, 22]. Briefly, the left femoral artery was cannulated with a
PE-50 catheter for blood pressure monitoring (transducer model
TNf, Gould Inc., Oxnard, California, USA) and blood sam-
pling. A solution of normal saline containing [methoxy-3H]
inulin (4 Ci/ml) and p-aminohippurate (PAH, 20 mg/ml; Merck
Sharpe & Dohme, West Point, Pennsylvania, USA) was infused
at a rate of 1.2 ml/hr after a priming dose of 0.5 ml. To maintain
euvolemia, 5% bovine serum albumin in normal saline (Sigma
Chemical Co., St. Louis, Missouri, USA) was infused at 1.5
mllhr after a priming dose of 1% body weight. Timed urine
collections were obtained from the left ureter for gravimetric
determination of urine flow rate, with blood collected at the
midpoint of each clearance period (250 jd).
Analytical techniques
Radioactivity in urine and serum was quantitated by liquid
scintillation counting. PAH levels in urine and serum were
determined by AutoAnalyser (Technicon, Tarrytown, New
York, USA). Urine sodium was determined by flame photom-
eter (Instrumentation Laboratory, Lexington, Massachusetts,
USA). Urinary total protein excretion was assayed by the
Coomassie dye method (Bio-Rad Laboratories, Richmond,
California, USA). Glomerular filtration rate (GFR), renal
plasma flow (RPF) and filtration fraction (FF) were calculated
with standard formulae. Renal blood flow was calculated by
dividing RPF by 1-hematocrit and renal vascular resistance
(RVR) by dividing MAP by RBF.
Urine was collected for 24 hours in sterile tubes containing
antibiotic/antimycotic solution (100 U/ml penicillin, 100 U/mI
streptomycin and 0.25 g/ml amphotericin B). Urine samples
were assayed for the stable NO metabolic end-products, NO2
and NO3, as previously described [16, 17]. Briefly, samples
were incubated for one hour at 37°C with E. coli nitrate
reductase, prepared from bacteria grown under anaerobic con-
ditions, effecting complete reduction of NO3 in the sample to
NO2. Total NO2 in the sample was then quantitated using the
Griess reagent. The NO2 measured in this way reflects the sum
of NO2 and NO3 in the original sample. Known concentrations
of NaNO2 and NaNO3 were utilized as standards in each assay
and each sample was run in duplicate. Urinary excretion rate
was calculated by multiplying the concentration of NO2 and
NO3 in each sample by the 24-hour urine flow rate.
Morphology
After completion of clearance studies the left kidney was
removed, weighed and the tissue fixed by immersion in buffered
formaldehyde solution. Renal tissue was sectioned at 3 m and
stained with the periodic acid-Schiff technique. All tissues were
evaluated without knowledge of the group to which the rat
belonged. Glomeruli were evaluated by systematic scanning of
both cortical and juxtaglomerular regions. Glomerulosclerosis
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Table 1. Physical parameters of rats
Group
Bod
Initial
y wt
Final
Left
kidney wt
g
UNaV
,nEq/day
Control 226 5 427 4 1.65 0.06 2.36 0.10
(N =8)
Salt 228 6 411 13 1.80 0.09 15.21 0.99a(N=8)
NAME 252 6 373 11 1.42 0.10 0.89 0.15
(N =8)
SaIt+NAME 227 4' 401 14 1.8 0.09 12.13 157a,b
(N = 8)
Salt+NAME+ 250 4 408 10 1.56 0.06 12.01 148a.b
L-ARG
(N = 6)
Values are at eight weeks except for initial body wt. Abbreviations
are: wt, weight; UNaV, urinary sodium excretion rate.
a P < 0.05 vs. Control
b P < 0.05 vs. NAME
was defined as the disappearance of cellular elements from the
tuft, collapse of capillary lumens, and folding of the glomerular
basement membrane with the entrapment of amorphous mate-
rial. A semiquantitative scoring technique evaluating the per-
centage of glomeruli with sclerosis and the extent of involve-
ment of each glomerulus was used as previously described [32].
Statistical analysis
Data are presented as mean SEM. Parameters between
groups were compared by analysis of variance and subsequent
Scheffe's test. Parameters within one group at different time
points were compared by analysis of variance for repeated
measures. All statistical analyses were done with STATVIEW
512 software (Brainpower Inc., Calabasas, California, USA).
Differences were considered significant for P < 0.05.
Results
At the time of randomization into the five experimental
groups baseline body wt (Table 1) and urinary sodium excretion
rate (Control, 0.90 0.13 mEq/day; Salt 0.84 0.10 mEq/day;
NAME, 0.51 0.12 mEq/day; Salt+NAME, 0.91 0.10
mEq/day; Salt+NAME+L-Arg, 1.27 0.14 mEq/day, P = NS)
were similar in all groups. Physical parameters of rats after
eight weeks on the experimental protocol are shown in Table 1.
There were no significant differences in final body wt between
any groups. High dietary salt intake was associated with a
tendency to increased kidney wt in Salt and Salt+NAME rats,
although these differences did not achieve statistical signifi-
cance. As expected, urinary sodium excretion rates were sig-
nificantly increased in all rats on 4% salt chow, compared to
Control and NAME rats. Thus, the high salt diet increased
sodium excretion five- to sixfold, and this was not significantly
affected by the presence of NOS inhibition.
Awake, systolic blood pressures in the five experimental
groups over the course of the study are shown in Figure 1. As
can be seen, blood pressure was similar in Salt and Control rats
at all time points (Fig. 1A). Thus, as expected, normal Sprague-
Dawley rats did not demonstrate a pressor response to in-
creased dietary salt intake alone. At two weeks, blood pressure
was equivalently increased in NAME and Salt+NAME rats
(Fig. lB), reflecting chronic NOS inhibition [30, 31]. However,
as can be seen (Fig. 1B), at 4, 6 and 8 weeks, rats exposed to a
high salt diet and NOS inhibition (Salt+NAME) had a marked
and significant increase in blood pressure compared to rats with
sitnilar NOS inhibition but consuming a standard salt diet
(NAME). Thus, when sodium intake was increased in rats with
intact NOS activity, there was no effect on blood pressure.
However, in the presence of NOS inhibition, Sprague-Dawley
rats become sensitive to the pressor effects of increased sodium
intake. At the initial dose of L-arginine (10-fold excess over
L-NAME), the Salt+NAME+L-ARG rats developed hyperten-
sion that was similar in magnitude to Salt+NAME rats (Fig.
lB). At three weeks, the dose of L-arginine was increased to 20
glliter (2%) in the drinking water. As can be seen, by six weeks
blood pressure in these L-arginine supplemented animals de-
creased to levels no different from those receiving L-NAME
alone, despite the high salt intake.
Urinary excretion rates of NO2 and NO3 at baseline, 2 and 8
weeks are shown in Figure 2. Baseline NO2 and NO3 excretion
was similar in all five groups. By two weeks, urinary NO2 and
NO3 excretion was significantly increased in Salt as compared
to Control rats and this difference persisted at eight weeks.
Urinary NO2 + NO3 excretion rate increased somewhat with
time in Control rats, consistent with normal growth (unpub-
lished observations). In NAME rats, the urinary NO2 + NO3
excretion rate was significantly decreased compared to Control
rats at two and eight weeks, confirming significant NOS inhibi-
tion. Urinary excretion of NO2 and NO3 was significantly lower
in Salt+NAME rats as compared to Salt rats at both two and
eight weeks. As can be seen, at eight weeks supplementation
with excess L-arginine completely restored the normal NO2 +
NO3 response to a high salt intake. Thus, increased dietary salt
intake was associated with a sustained increase in NO activity
in normal Sprague-Dawley rats, and this salt-induced increase
in NO production was prevented by chronic NOS inhibition
with L-NAME.
Figure 3 shows the relationship between systolic blood pres-
sure and urinary NO2 + NO3 excretion rate in Control and
NAME rats. As can be seen, there was a significant negative
correlation of these two parameters. Thus, in normal rats and
during inhibition of NOS, systolic blood pressure was corre-
lated with the activity of the endogenous NO system.
Renal hemodynamic parameters at the end of the eight week
protocol are shown in Table 2. Mean arterial pressure was not
different between Salt and Control rats. MAP was significantly
higher in NAME as compared to Control rats, reflecting signif-
icant NOS inhibition. In the presence of NOS inhibition, a high
salt intake (Salt+NAME) significantly increased intra-arterial
pressure compared to NAME alone (P < 0.05), but this effect
was reversed by simultaneously providing excess L-arginine
(Salt+NAME+L-ARG). Thus, direct intra-arterial measure-
ments under anesthesia confirmed that NOS inhibition induced
a sensitivity to the pressor effects of high salt intake that was
not observed in normal rats. As can be seen in Table 2,
increased dietary salt intake alone (Salt) did not significantly
effect any parameter of renal function as compared to Control
rats. There was a tendency for a reduced GFR in Salt+ NAME
rats compared to the other groups which did not achieve
statistical significance. NAME alone numerically reduced RPF
and increased RVR and FF; however, these changes were not
1•
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Fig. 2. Urinary NO2 and NO3 excretion rate at baseline, 2 and8 weeks
in rats on normal (Control, LI; NAME) or high salt (Salt,
Salt+NAME, Salt+NAME+L-ARG) diets. NAME (), Salt+NAME
(a), and SaIt+NAME+L-ARG (LI) rats were also treated with the NO
synthase inhibitor, L-NAME provided in the drinking water. J3 < 0.05
vs. Control. tP < 0.05 Salt vs. Salt+NAME.
statistically significant. In Salt+NAME rats, there was a signif-
icant reduction in RPF and increased in RVR and FF as
compared to Control rats. In Salt+NAME+L-ARG rats, renal
hemodynamic parameters were not different from those ob-
served in Control rats, or rats on a high salt diet with intact
NOS activity.
Figure 4 shows urinary protein excretion rates at eight weeks
in the experimental groups. There was no significant difference
in urinary protein excretion rate between Control, Salt or
NAME rats, although the level of proteinuria was approxi-
mately twofold greater in NAME as compared to Control rats.
However, proteinuria was markedly and significantly increased
in magnitude in Salt+NAME rats. In Salt+NAME+L-ARG
rats, urinary protein excretion was not different from Control
rats. Thus, neither a high salt intake nor NOS inhibition alone
induced a significant increase in proteinuria. However, protein-
uria was markedly increased when salt intake was increased in
the presence of NOS inhibition.
Vascular and tubular structures were essentially normal in
Control and Salt rats. In both these groups, occasional glomer-
uli showed segmental areas of sclerosis, however, there was no
difference in the overall degree of injury (glomerular injury
Fig. I. Awake systolic blood pressures in rats
during 8 weeks experimental protocol. (A)
Rats on normal (Control; LI; 0.4% NaC1) and
high salt (Salt; U; 4% NaCI) diets. (B) Rats
given L-NAME and either normal (NAME;
LI), or high salt (Salt+NAME; U) diets. An
additional group received high salt diet with
both L-NAME (25 mg/liter) and L-arginine
(2%) in the drinking water (Salt+NAME+
L-ARG; ). *D < 0.05 Salt+NAME vs.
NAME, tP < 0.05 Salt+NAME+L-ARG vs.
NAME.
score: Control 59 9; Salt 59 8, P = NS). In groups with
NOS inhibition, NAME and Salt+NAME, rats demonstrated a
modest, but similar, degree of tubular dilation, atrophy and cast
formation. Both groups showed arteriolar thickening as well.
There was a tendency for increased mean glomerular injury
score in NAME (99 10) and Salt+NAME (79 17) rats
compared to Controls; however, these differences were only of
borderline significance by ANOVA (P = 0.06). There was a
large degree of variability in the extent of renal injury in
Salt+NAME rats. In two of the Salt+NAME rats, marked
glomeruloscierosis was observed in combination with vascular
injury consisting of arteriolar thickening, intimal proliferation
and fibrinoid necrosis. These malignant changes were not found
in any rats from other experimental groups. In Salt+NAME+L-
ARG rats, the glomerular injury score was not significantly
different from Controls (81 9, P = NS).
Discussion
A possible association between salt intake and hypertension
has been recognized for many years [33]. It has been hypothe-
sized that this association is related to a defect in renal sodium
excretion which alters the set point at which arterial pressure is
maintained [34—36]. According to this "renal-body fluid feed-
back control of arterial pressure" hypothesis, when the normal
B
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Fig. 3. Regression line of urinary NO2 + NO3 excretion rate on
systolic blood pressure in Control and NAME rats. All rats were on a
normal salt diet, and NAME rate were given the NO synthase inhibitor,
L-NAME, in the drinking water. r2 = 0.217; P < 0.001.
Control Salt NAME Salt Salt
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Group
MAP
mm Hg
GFR RPF
mi/mm
RVR
mrnHg
mm/mi FF
Control 124 1.01 6.43 10.19 0.15
(N =8) 3 0.05 0.28 0.71 0.01
Salt 124 1.08 7.89 8.33 0.14
(N = 8) 4 0.03 0.45 0.36 0.01
NAME 152 1.16 5.65 14.47 0.20a
(N = 6) 9 0.08 0.34 1.51 0.01
Salt+NAME 183a,b 0.79 3.98a 27.7a 0.24a
(N = 8) 12 0.16 0.60 8.27 0.03
Salt+NAME+ l40C 1.08 7.29C l3.4T 0.16c
L-Arg 4 0.05 1.20 1.94 0.02(N=6)
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular
filtration rate; RPF, renal plasma flow; RVR, renal vascular resistance;
FF, filtration fraction.
a p < 0.05 vs. Controlb P < 0.05 vs. NAME
' P < 0.05 Salt+NAME+L-ARG vs. Salt+NAME
natriuretic responses to an increase in salt intake are deficient,
a sustained increase in arterial pressure is required to restore
sodium balance through a pressure-natriuresis mechanism.
Thus, sensitivity to the pressor effects of a high salt intake could
be due to lack of an adaptative increase in sodium excretion by
the kidney. The pathogenesis of this proposed lack of adapta-
tion and why it appears in only certain patients with, or
experimental models of, hypertension [37] remain unclear.
A large body of recent experimental data has suggested that
the endogenous mediator, NO, plays an important role in
control of renal hemodynamics and in modulation of renal
sodium excretion [14, 17, 21—27, 38]. As noted above, it has
become apparent that stimulation of NO production results in
renal vasodilation, natriuresis and diuresis; NOS inhibition has
the opposite effects, causing not only renal vasoconstriction,
but, when renal perfusion pressure remains constant, decreased
sodium and water excretion as well. We recently reported [17]
that in normal rats, exposure to a high dietary salt intake for two
weeks resulted in increased endogenous NO production. We
suggested that in normal rats the NO system participates in the
physiologic renal adaptation to increased dietary salt intake,
perhaps preventing a systemic pressor response by facilitating
sodium excretion. In the current study, we examined whether
normally salt-resistant Sprague-Dawley rats would become
sensitive to the pressor effects of increased salt intake if the
expected adaptive increase in NO production was prevented by
administering an exogenous NOS inhibitor.
Our results demonstrate that the normal Sprague-Dawley rat
adapts efficiently to increased salt intake, even over a prolonged
period. Rats exposed to a high salt intake alone for eight weeks
had no increase in systemic blood pressure compared to Con-
trol rats consuming a diet with normal salt content. Similarly,
increased salt intake did not significantly affect any parameter
of renal function determined at eight weeks as determined by
clearance techniques. The current study confirms and extends
our previous observation [17] that increased salt intake is
associated with increased endogenous NO production, as re-
flected in markedly increased urinary excretion of NO2 and
+NAME +NAME
+L-ARG
Fig. 4. Urinapy protein excretion rate at 8 weeks in rats on normal
(Control, NAME) or high salt (Salt, Salt+NAME, Salt+NAME+L-
ARG) diets. NAME, Salt+NAME and Salt±NAME+L-ARG rats were
also treated with the NO synthase inhibitor, L-NAME, provided in the
drinking water. * P < 0.05 vs. Control.
NO3 in Salt as compared to Control rats (Fig. 2). This effect was
sustained for the entire eight week experimental protocol.
Prolonged exposure to a high dietary salt intake alone did not
result in renal injury, as reflected in urinary protein excretion
rates and glomerular injury scores that were not different from
Control rats. Thus, in normal Sprague-Dawley rats with intact
ability to adaptively increase NO production, chronically in-
creased dietary salt intake does not result in hypertension or
renal injury.
Baylis, Mitruca and Deng [30] demonstrated that long-term
oral administration of L-NAME in the rat results in systemic
hypertension, proteinuria and glomeruloscierosis. These
changes were associated with a decrease in GFR, renal vaso-
constriction and an increase in FF. On a microcirculatory level,
single nephron GFR decreased due to a fall in both glomerular
capillary plasma flow (QA) and ultrafiltration coefficient (Kf).
Glomerular capillary pressure was increased. Similar findings
were reported by Rjbeiro, Antunes and deNucci [31]. Thus, it
seems apparent that the increase in systemic blood pressure
during chronic NOS inhibition is transmitted to the glomerular
capillaries resulting in proteinuria and glomerular injury. In
support of this concept, we recently reported [17] that in the rat,
acute, intrarenal infusion of an NOS inhibitor resulted in a
significant increase in urinary protein excretion rate. This
proteinuric effect of NOS inhibition was not observed when the
associated increase in renal perfusion pressure and, presum-
ably, glomerular capillary pressure, was prevented with a
suprarenal aortic snare.
In the current study, L-NAME was administered in a lower
dose than in previous studies [30, 31]. This dose induced an
increase in blood pressure, while urinary excretion of the stable
NO metabolites, NO2 and NO3, was decreased in NAME as
compared to Control rats at both two or eight weeks. Further-
more, the increase in NO2 and NO3 excretion observed during
high dietary salt intake in Salt rats was completely prevented at
both these time points in Salt+NAME rats (Fig. 2). Thus,
chronic administration of oral L-NAME prevented the adaptive
increase in NO synthesis expected in normal rats given a high
Table 2. Renal hemodynamic parameters at eight weeks
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dietary salt intake. Supplying excess exogenous NO substrate
in the form of L-arginine restored the ability to respond to a
high salt diet with an increase in activity of the endogenous NO
system. That the increase in urinary NO2 and NO3 excretion
observed during increased dietary salt intake was prevented by
an NOS inhibitor and restored by 1-arginine supplementation
further confirms that this increase is specifically due to in-
creased endogenous NO production.
After eight weeks, blood pressure was elevated in NAME as
compared to Control rats, and a tendency toward proteinuria
and glomerulosclerosis was observed. GFR was unchanged;
however, RPF tended to decrease while FF and RVR tended to
increase. Thus, during chronic NOS inhibition alone, we ob-
served changes in blood pressure and renal function that were
similar in direction, but of lesser magnitude than those previ-
ously reported [30, 31].
In contrast to rats with intact NOS activity (Salt), a high
dietary salt intake during NOS inhibition had a clear and
dramatic pressor effect (Fig. 1) that persisted for the entire
eight-week experimental protocol. Thus, we have demonstrated
that rats which are normally resistant to the hypertensive
effects of salt become salt-sensitive when NO synthesis is
impaired. This observation is consistent with, and complemen-
tary to, the findings of Chen and Sanders [28] in which they
demonstrated that Dahi S rats that are genetically predisposed
to be sensitive to the pressor effects of high dietary salt intake
have an impaired endogenous NO system. This suggests that
impaired NOS responses to increased dietary salt intake may be
a common underlying mechanism in salt-sensitive hyperten-
sion. Furthermore, it raises the possibility that a genetically
determined defect in basal NOS activity, or in the induction of
NOS activity in response to environmental factors, may be
pathogenetic in some hypertensive states.
When a high salt diet is combined with impaired NOS
activity, our data also suggest that the degree of renal injury
may be more severe. Proteinuria was markedly increased in
Salt+NAME rats after eight weeks. Although the mean glomer-
ular injury score was not significantly increased in Salt+NAME
rats as compared to Controls, a subset of these rats had
morphologic changes consistent with malignant hypertension,
demonstrating marked degrees of vascular injury and glomeru-
losclerosis. These changes were not observed in rats receiving
NAME alone. Furthermore, Salt+NAME rats demonstrated
renal functional changes consistent with renal injury. Although
not demonstrated in the current experiment, it is possible that
over a more prolonged time period the combination of NOS
inhibition and a high salt diet could be particulary injurious to
the kidney.
In summary, we have demonstrated that Sprague-Dawley
rats are normally resistant to the pressor effect of increased
dietary salt intake, and that this resistance is associated with
sustained, adaptive increases in NO production. When in-
creases in NO activity are prevented by chronic treatment with
a NOS inhibitor, these rats become sensitive to the pressor
effect of increased salt intake, developing hypertension and
subsequent renal injury. We conclude that adaptive changes in
endogenous NO production play a critical role in sodium
balance and blood pressure homeostasis. Furthermore, im-
paired NO synthase activity may be a pathogenetic factor in the
development of salt-sensitive hypertension. The general appli-
cability of this concept to experimental models of hypertension
and to the pathogenesis of human disease will need to be
examined in future studies.
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